The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000162.5(GCK):c.1113C>A (p.Cys371Ter)

CA367398930

617645 (ClinVar)

Gene: GCK
Condition: monogenic diabetes
Inheritance Mode: Semidominant inheritance
UUID: d3ce12e9-9571-487e-9837-de8a67580d76

HGVS expressions

NM_000162.5:c.1113C>A
NM_000162.5(GCK):c.1113C>A (p.Cys371Ter)
NC_000007.14:g.44145637G>T
CM000669.2:g.44145637G>T
NC_000007.13:g.44185236G>T
CM000669.1:g.44185236G>T
NC_000007.12:g.44151761G>T
NG_008847.1:g.48787C>A
NG_008847.2:g.57534C>A
ENST00000395796.8:c.*1111C>A
ENST00000616242.5:c.*233C>A
ENST00000683378.1:n.339C>A
ENST00000336642.9:c.147C>A
ENST00000345378.7:c.1116C>A
ENST00000403799.8:c.1113C>A
ENST00000671824.1:c.1176C>A
ENST00000672743.1:n.125C>A
ENST00000673284.1:c.1113C>A
ENST00000336642.8:n.165C>A
ENST00000345378.6:c.1116C>A
ENST00000395796.7:c.1110C>A
ENST00000403799.7:c.1113C>A
ENST00000437084.1:c.1062C>A
ENST00000459642.1:n.493C>A
ENST00000616242.4:n.1110C>A
NM_000162.3:c.1113C>A
NM_033507.1:c.1116C>A
NM_033508.1:c.1110C>A
NM_000162.4:c.1113C>A
NM_001354800.1:c.1113C>A
NM_001354801.1:c.102C>A
NM_001354802.1:c.-28C>A
NM_001354803.1:c.147C>A
NM_033507.2:c.1116C>A
NM_033508.2:c.1110C>A
NM_033507.3:c.1116C>A
NM_033508.3:c.1110C>A
NM_001354803.2:c.147C>A

Pathogenic

Met criteria codes 3
PVS1 PM2_Supporting PP4_Moderate

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Monogenic Diabetes Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for GCK Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Monogenic Diabetes VCEP
The c.1113C>A variant in the glucokinase gene, GCK, results in a premature termination at codon 371 (p.(Cys371Ter)) of NM_000162.5. This variant, located in biologically-relevant exon 9/10, is predicted to lead to nonsense-mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; internal lab contributors). In summary, this variant meets the criteria to be classified as pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.2.0, approved 6/7/2023): PVS1, PM2_Supporting, PP4_Moderate.
Met criteria codes
PVS1
This variant, located in biologically-relevant exon 9/10, is predicted to lead to nonsense-mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1).
PM2_Supporting
This variant is absent from gnomAD v2.1.1 (PM2_Supporting).
PP4_Moderate
This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; internal lab contributors).
Approved on: 2023-08-09
Published on: 2023-08-10
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.